Pyxis Oncology, Inc. (PYXS)
Market Cap | 228.49M |
Revenue (ttm) | 16.15M |
Net Income (ttm) | -57.80M |
Shares Out | 58.89M |
EPS (ttm) | -1.36 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 314,533 |
Open | 3.950 |
Previous Close | 3.850 |
Day's Range | 3.810 - 4.050 |
52-Week Range | 1.350 - 6.850 |
Beta | 1.28 |
Analysts | Strong Buy |
Price Target | 9.83 (+153.35%) |
Earnings Date | Aug 9, 2024 |
About PYXS
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumo... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for PYXS stock is "Strong Buy." The 12-month stock price forecast is $9.83, which is an increase of 153.35% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/u/t/press6-2502813.jpg)
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reporte...
![](https://cdn.snapi.dev/images/v1/q/n/press17-2470767.jpg)
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today...
![](https://cdn.snapi.dev/images/v1/w/t/conf11-2453357.jpg)
Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announce...
![](https://cdn.snapi.dev/images/v1/d/d/press18-2429059.jpg)
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106 Pha...
![](https://cdn.snapi.dev/images/v1/w/o/conf9-2420582.jpg)
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announce...
![](https://cdn.snapi.dev/images/v1/a/o/press15-2343625.jpg)
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen's l...
![](https://cdn.snapi.dev/images/v1/u/u/press15-2334950.jpg)
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
PYX-201 Phase 1 Part 1 trial progressing with initial data expected in the fall of 2024 PYX-106 Phase 1 trial progressing with initial data expected 2H 2024 Completed $50 million private placement Exp...
![](https://cdn.snapi.dev/images/v1/i/m/press5-2321938.jpg)
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, toda...
![](https://cdn.snapi.dev/images/v1/q/q/conf5-2314326.jpg)
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
BOSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announ...
![](https://cdn.snapi.dev/images/v1/p/f/conf12-2309717.jpg)
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
PYX-201, an EDB+FN-specific tumor stroma-targeting ADC, demonstrates potent anti-tumor efficacy across multiple human cancers in PDX tumor models
![](https://cdn.snapi.dev/images/v1/f/7/press5-2145451.jpg)
Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
PYX-201 (a novel first-in-concept and first-in-class tumor stroma targeting antibody-drug conjugate [ADC] product candidate) Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg ; data expect...
![](https://cdn.snapi.dev/images/v1/o/i/press20-2079865.jpg)
Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today ...
![](https://cdn.snapi.dev/images/v1/t/l/press7-2073889.jpg)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ: PYXS)
NEW YORK , Sept. 21, 2023 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Pyxis Oncology, Inc. (NASDAQ: PYXS) concerning possible breaches of fiduciary duty.
![](https://cdn.snapi.dev/images/v1/3/r/press10-2045750.jpg)
Pyxis Oncology to Participate in Two Upcoming Investment Conferences
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today a...
![](https://cdn.snapi.dev/images/v1/a/s/press6-2034040.jpg)
Pyxis Oncology Successfully Completes Acquisition of Apexigen
Transaction adds a validated antibody-discovery platform, Phase 2 candidate and royalty stream Company positioned as a leader in next-generation, end-to-end Antibody-Drug Conjugate (“ADC”) creation wi...
![](https://cdn.snapi.dev/images/v1/i/p/press16-2019176.jpg)
Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update
Third dose cohort initiated in Phase 1 trial of PYX-201, Pyxis Oncology's first ADC product candidate Preliminary data from two Phase 1 trials on track for late 2023 to early 2024 Apexigen transaction...
![](https://cdn.snapi.dev/images/v1/s/p/press18-2018185.jpg)
APEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apexigen, Inc. (...
![](https://cdn.snapi.dev/images/v1/z/o/conf1-1999830.jpg)
Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference
BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today a...
![](https://cdn.snapi.dev/images/v1/o/p/press7-1963599.jpg)
CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan
The two industry leaders focus on navigating the biotech industry and immuno-oncology research The two industry leaders focus on navigating the biotech industry and immuno-oncology research
![](https://cdn.snapi.dev/images/v1/d/b/press3-1913452.jpg)
APEXIGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apexigen, Inc. (...
![](https://cdn.snapi.dev/images/v1/x/w/press2-1912090.jpg)
Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs
First subject dosed in Phase 1 trial of PYX-106, a fully human immunotherapy antibody candidate Second dose level initiated in Phase 1 trial of PYX-201, an antibody-drug conjugate (ADC) candidate Prel...
![](https://cdn.snapi.dev/images/v1/z/q/press17-1904795.jpg)
Pyxis Oncology to Acquire Apexigen
Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate (ADC) development Commercially and clinically validated APXiMAB platform for antibody generation complements FACT ADC toolkit of linke...
![](https://cdn.snapi.dev/images/v1/r/n/press6-1884622.jpg)
Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update
Orphan Drug Designation received for PYX-201 in pancreatic cancer Preliminary data from two Phase 1 trials anticipated late 2023 to early 2024 Strong balance sheet with $150.8 million in cash (includi...
![](https://cdn.snapi.dev/images/v1/o/3/press2-1807285.jpg)
Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update
Preliminary data from two Phase 1 trials anticipated late 2023 to early 2024
![](https://cdn.snapi.dev/images/v1/v/5/press1-1799729.jpg)
Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
Milestone marks transition of Pyxis Oncology to a clinical-stage company